As a reminder, effective October 1, 2024, Carelon Medical Benefits Management will expand multiple programs to perform medical necessity reviews for additional procedures for Anthem members. Carelon Medical Benefits Management works to improve healthcare quality and manage costs for today’s most complex and prevalent tests and treatments, helping to promote care that is appropriate, safe, and affordable.

The continued migration will expand clinical appropriateness review for procedures related to the following existing Carelon Medical Benefits Management programs: cardiovascular, musculoskeletal, radiation oncology, radiology, sleep, and surgical. In addition, some codes will migrate into a new Carelon Medical Benefits Management solution — additional outpatient utilization management (UM) that will include some transportation (including ambulance) and fertility procedures as set forth below. Transportation may include emergency post-service reviews.

The Clinical UM Guidelines and Medical Policies (also known as coverage guidelines in Virginia) by Anthem for medical necessity review are listed in the table below. Carelon Medical Benefits Management will begin accepting prior authorization requests on September 23, 2024, for dates of service on or after October 1, 2024.

Members included in the new program

Updates to Carelon Medical Benefits Management programs apply to select local fully insured Anthem members and select members who are covered under self-insured (ASO) benefit plans with services medically managed by Carelon Medical Benefits Management. This notice does not apply to certain HMO, BlueCard^®, Medicare Advantage, Medicaid, Medicare Supplemental, or Federal Employee Program^® (FEP^®). For more information, please contact the phone number on the back of the member ID card.

Pre-service review requirements

For procedures that are scheduled to begin on or after October 1, 2024, all care providers must contact Carelon Medical Benefits Management to obtain pre-service review for the services including, but not limited to, the following non-emergency modalities. Please refer to the Clinical Guidelines at anthem.com > Providers > Provider Resources > Policies, Guidelines & Manuals for complete code lists.

Note: All codes will be reviewed for medical necessity for the requested service and not for site of care. Please note some services below are effective March 1, 2025.

Update to previous notice: The services additional outpatient utilization management and base surgical below are effective March 1, 2025.

To determine if prior authorization is needed for a member on or after October 1, 2024, contact the Provider Services phone number on the back of the member’s ID card for benefit information. Care providers using the Interactive Care Reviewer (ICR) tool on Availity.com to pre-certify an outpatient procedure will receive a message referring the provider to Carelon Medical Benefits Management. (Note: ICR cannot accept prior authorization requests for services administered by Carelon Medical Benefits Management.)

Care providers should continue to submit pre-service review requests to Carelon Medical Benefits Management using the convenient online service via the Carelon Medical Benefits Management provider portal. The provider portal is available 24 hours a day, seven days a week, processing requests in real-time using Clinical Criteria. Go to providerportal.com to register.

For more information

For resources to help your practice get started with the cardiology, musculoskeletal, radiology, sleep, surgical procedures, and radiation oncology programs, visit:

• Cardiovascular Solution | Carelon Insights
• Radiology Solution | Carelon Insights
• Sleep Solution | Sleep Healthcare | Carelon Insights
• Surgical Procedures Solution | Carelon Insights
• Radiation Oncology Solution | Carelon Insights
• Additional Outpatient Utilization Management

Our website at anthem.com helps you access information and tools such as order entry checklists, Clinical Guidelines, and FAQ. You can also contact your local network relations representative if you have any questions.

Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare.

Effective October 1, 2024, Carelon Medical Benefits Management, Inc. will expand multiple programs to perform medical necessity reviews for additional procedures for Anthem members. Carelon Medical Benefits Management works to improve healthcare quality and manage costs for today’s most complex and prevalent tests and treatments, helping to promote care that is appropriate, safe, and affordable.

The expansion will require clinical appropriateness review for additional procedures related to Carelon Medical Benefits Management programs, including cardiology, radiation oncology, radiology, musculoskeletal, sleep, surgical, and additional outpatient services.

Carelon Medical Benefits Management will follow the clinical hierarchy established by Anthem for medical necessity determination. Anthem makes coverage determinations based on CMS guidance, including national coverage determinations (NCDs), local coverage determinations (LCDs), other coverage guidelines and instructions issued by CMS, and legislative changes in benefits. When existing guidance does not provide sufficient clinical detail, Carelon Medical Benefits Management will determine medical necessity using an objective, evidence-based process.

Carelon Medical Benefits Management will continue to use criteria documented in the Medical Policies and Clinical Guidelines of Anthem listed in the table below. These Clinical Guidelines can be found at Availity.com.

Detailed prior authorization (PA) requirements are available online by accessing the Precertification Lookup Tool under Payer Spaces at Availity.com. Contracted and noncontracted care providers should call Provider Services at the phone number on the back of the member’s ID card for PA requirements.

Prior authorization review requirements

Carelon Medical Benefits Management will begin accepting PA requests on September 24, 2024, for dates of service October 1, 2024, and after. For procedures scheduled to begin on or after
October 1, 2024, care providers must contact Carelon Medical Benefits Management to obtain PA for the non‑emergency modalities below. Refer to the clinical guidelines on the microsite resource pages for complete code lists.

To determine if PA is needed for a member on or after October 1, 2024, call Provider Services using the phone number on the back of the member’s ID card. Care providers using the interactive care reviewer (ICR) tool on Availity.com for PA requests on an outpatient procedure will receive a message referring the provider to Carelon Medical Benefits Management (Note: ICR cannot accept PA requests for services administered by Carelon Medical Benefits Management).

How to place a review request

Care providers may place a PA request online to Carelon Medical Benefits Management by way of providerportal.com. ProviderPortal_SM is available 24/7, processing requests in real-time using clinical criteria.

For more information

For resources to help your practice get started with the cardiology, musculoskeletal, surgical, and programs, visit:

• Cardiovascular Solution | Carelon Insights
• Musculoskeletal (MSK) Solution | Carelon Insights (AIM)
• Sleep Solution | Sleep Healthcare | Carelon Insights
• Surgical Procedures Solution | Carelon Insights
• Radiation Oncology Solution | Carelon Insights

Our website helps you access information and tools such as order entry checklists, Clinical Guidelines, and FAQ.

Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare.

Soon you will be able to request your specific fee schedule via the Provider Enrollment application in Availity Essentials. Enter your organizational information in the My Fee Schedule option, where you will be able to request and download your contracted rate(s) at one centralized location:

• Care providers can download the complete fee schedule — both standard and negotiated rates — within minutes.
• Care providers will be able to pull historic fee schedules (up to three years), current, and future rate(s).
• Rates are updated daily and will be available the following day.

To locate Provider Enrollment, log in to Availity Essentials, select your state, then select Payer Spaces and payer tile. Look for future communications as to when this feature will be live.

We previously communicated to you that we are digitizing authorization case notifications, including status and decision letters, for Commercial health plans, eliminating paper notifications, with the commercial health plans. We are happy to share that we are expanding the digitization of authorization case notifications and eliminating paper notifications for Medicare health plans in your state.

Just as you have with Commercial health plans, you have 24/7 access to authorization case information in one location through Availity Essentials. The digital authorization case status notifications are available under the Authorizations and Referrals* application once you have logged in to Availity Essentials and selected Patient Registration. By eliminating the redundancy of receiving both a digital and paper letter, you’ll see fewer errors associated with manual processes in handling the paper letters while reducing cost and our carbon footprint.

* Note: to access this application, your Availity Essentials administrator must assign you the role of Authorization & Referral Inquiry or Request.

Care providers will be able to choose different options to receive Medicare authorization decision notifications via the Provider Preference Center under Availity Payer Spaces. Look for details on the Provider Preference Center options and ways to access authorization case status in an upcoming communication.

We are focused on reducing administrative burdens, so you can do what you do best — care for our members.

Effective for dates of service on and after November 17, 2024, the following updates will apply to the Carelon Medical Benefits Management Clinical Appropriateness Guidelines. As part of the Carelon Medical Benefits Management, Inc. guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable healthcare services.

Genetic testing

Cell-free DNA testing (liquid biopsy) for the management of cancer:

• Expanded criteria to include a wider scope of testing for metastatic disease: AKT1 and PTEN (related to capivasertib/fulvestrant therapy)

Prenatal testing (changed to screening) using cell-free DNA:

• Expanded criteria to include follow-up screening for abnormal maternal serum screen results in viable singleton/twin pregnancies when diagnostic testing is declined
• Expanded criteria to include screening for pregnancies with multiple anomalies when diagnostic testing is not possible

Somatic testing of solid tumors:

• Tissue-agnostic testing for patients with advanced solid tumors:
  • Clarification about TMB testing by FDA-approved test with reporting threshold ≥ 10 mutations/megabase (mut/Mb)
• Bladder cancer:
  • Expansive changes for microsatellite instability/mismatch repair deficiency (MSI/dMMR)
• Brain cancer:
  • New clinical criteria considered clarifications for what may have otherwise been reviewed using general (umbrella) criteria
• Breast cancer, metastatic:
  • Expanded criteria to include a wider scope of testing for metastatic disease: AKT1 and PTEN (related to capivasertib/fulvestrant therapy)
• Colorectal cancer (CRC), localized and metastatic:
  • Newly diagnosed localized or metastatic CRC — expanded criteria for MSI/dMMR testing to allow in individuals with de novo metastatic disease
  • Metastatic CRC — expanded POLE/POLD1 testing
• Endometrial carcinoma:
  • Expanded routine testing for MSI/dMMR; also expanded POLE and p53 testing
  • Panel size limited to ≤ 50 genes
• Non-small cell lung cancer, metastatic:
  • New criteria for metastatic squamous cell carcinoma
  • Allowance for repeat next-generation sequencing (NGS) testing in the setting of progressive disease, if a progressing lesion is being used for the repeat testing
• Ovarian (epithelial):
  • Added statement that homologous recombination deficiency (HRD) testing must include evaluation of genomic instability through an FDA approved test
• Pancreatic adenocarcinoma:
  • Added criteria for targeted (50 or fewer genes) somatic testing beyond MSI/dMMR in locally advanced, metastatic, or recurrent pancreatic adenocarcinoma
• Prostate cancer, metastatic:
  • Specified appropriateness of MSI/dMMR testing is in metastatic prostate cancer
  • Moved ataxia-telangiectasia mutated (ATM) from required to "may be included" genes in approvable NGS panels
• Thyroid cancer:
  • Testing of indeterminate thyroid nodules (ITN) — Afirma GSC added as a gene expression classifier that may be used
  • Somatic testing of thyroid malignancy — modified language so that BRAF V600E, ALK, NTRK, and RET testing can be done in anaplastic thyroid cancer at any stage, or in unresectable, locally advanced, recurrent, or metastatic thyroid cancer

Somatic testing of hematologic malignancies:

• Acute lymphocytic leukemia:
  • Added statement about NGS testing on bone marrow specimen which specifies time points where testing is appropriate (such as end of initial induction, end of initial consolidation)
• Acute myelogenous leukemia:
  • Added an indication for focused testing using RT-qPCR to measure minimal residual disease (MRD)
• Chronic myeloid leukemia:
  • Modified the timing for BCR-ABL1 quantification for monitoring in the first year after completion of tyrosine kinase inhibitor (TKI) therapy
  • Added allowance for BCR-ABL1 quantification for monitoring patients at three-month intervals beyond one year after completion of TKI therapy
• Myeloproliferative neoplasms:
  • Added allowance for additional focused testing for initial risk stratification if a specific myeloproliferative neoplasm is diagnosed on initial diagnostic workup
• Myelodysplastic syndrome (MDS):
  • Clarified that testing can be pursued for diagnosis or risk stratification and clarified the list of genes that may be associated with MDS

Musculoskeletal

Joint surgery:

• Reverse shoulder arthroplasty:
  • Added a requirement for impaired function for six months for consistency with total shoulder arthroplasty
  • Removed requirement for conservative management when there is severe osteoarthritis for consistency with other joint replacements
• Shoulder arthroscopy and open procedures:
  • Removal of loose body — removed requirement for specific findings on exam
  • Rotator cuff repair and revision — added an exclusion for subacromial balloon spacer due to lack of supporting evidence
  • Labrum repair — removed Bankart lesion broadening MRI findings to allow for any labral tear
  • Chronic shoulder instability or laxity — broadened exam findings to include any evidence of instability rather than just the apprehension/relocation test
  • Tendinopathy of the long head of the biceps — removed specific exam findings related to long head of biceps pathology
• Primary total hip arthroplasty:
  • Removed the requirements for conservative management and three-month duration of symptoms when radiographs show severe osteoarthritis
• Primary partial hip arthroplasty:
  • Combined criteria for partial hip arthroplasty and partial hip resurfacing
• Hip arthroscopy:
  • Removal of loose body — removed requirement for specific findings on exam
• Knee arthroplasty:
  • Added exclusion for the use of an implantable shock absorber due to lack of supporting evidence
• Knee arthroscopy:
  • Anterior cruciate ligament (ACL) reconstruction — removed standalone scenario of physically demanding occupation/pattern of activities
  • Excision of popliteal cyst — added imaging requirement
  • Repair of subchondral bone defects (subchondroplasty) — added exclusion for use of engineered calcium phosphate mineral or similar compounds due to lack of supporting evidence
• Osteochondral grafts:
  • Juvenile osteochondritis dissecans — expanded allowances to include either failed conservative management or unstable lesion
  • Added exclusion for use of particulated juvenile articular cartilage due to lack of evidence supporting its use

Small joint surgery:

• Hallux rigidus surgery:
  • First metatarsophalangeal joint arthrodesis — removed three-month requirement for conservative management (not needed with severe osteoarthritis)
  • First metatarsophalangeal joint arthroplasty — removed three-month requirement for conservative management; added allowance for failed prior hallux rigidus surgery
• Ankle arthritis:
  • Ankle arthrodesis and total ankle arthroplasty — removed requirement for conservative management when there is severe osteoarthritis for consistency with other joint replacements
  • Revision total ankle arthroplasty — added requirement for reconstruction after the management of periprosthetic infection to be consistent for staged reconstructions of infected total ankle

Surgical site of care:

• Criteria have been reformatted to align with general categories that are used across all Carelon Medical Benefits Management Site of Care Guidelines.
• Background, Scope, and Rationale sections have been updated and aligned with all Carelon Medical Benefits Management Site of Care Guidelines.
• Clinical comorbidities have been broadened to include any American Society of Anesthesiologists (ASA) Class III or greater condition with specific examples updated as below:
  • The following cardiac comorbidity examples were removed and replaced with “documented history of myocardial infarction or acute coronary syndrome”:
    • “Acute coronary syndrome within the prior three months”
    • Currently taking dual antiplatelet therapy which cannot be temporarily discontinued safely for the proposed surgical procedure
    • Ongoing ischemic symptoms
  • The cerebrovascular example was changed from “Stroke or transient ischemic attack (TIA) within the prior three months” to “Documented history of stroke or transient ischemic attack (TIA).”
• The criteria “mental status change” was removed due to redundancy with existing criteria of “intellectual disability or cognitive impairment.”
• Criteria added for “when performing a procedure outside the Hospital Outpatient Department (HOPD) would reasonably be expected to create clinically significant delays in care.”
• Criteria added for “Absence of a geographically accessible alternative non-HOPD facility capable of performing the requested procedure.”

Advanced imaging site of care:

• Background, Scope, and Rationale sections have been updated and aligned with all Carelon Medical Benefits Management Site of Care Guidelines.
• Criteria was added for “Additional resources required to establish and/or maintain IV access in patients with previous difficulty.”

How to submit prior authorization requests, ask questions, or get more information

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management using the following:

• Access the Carelon Medical Benefits Management provider portal directly at providerportal.com:
  • Online access is available seven days a week, 24 hours a day to process orders in real-time and is the fastest and most convenient way to request authorization.

If you have questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines on the Carelon Medical Benefits Management website.

Effective September 1, 2024, Anthem will upgrade to the 28th edition of MCG Care Guidelines. Along with this upgrade, there will be some changes as to how transcranial magnetic stimulation (TMS) will be approved.

A specific change will be noted for Behavioral Health Care (BHG): Transcranial Magnetic Stimulation B-801-T. An annotation for motor threshold redetermination after initiation of treatment has been added to the Inconclusive or non-supportive evidence section of the evidence summary with new references to support it.

Any requests for CPT^® code 90869 will be referred for peer clinical review to determine medical necessity.

If you have questions, please contact Provider Services by calling the number on the back of the member's ID card.

Effective for dates of service on and after November 17, 2024, the following updates will apply to the Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines. As part of the Carelon Medical Benefits Management guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable healthcare services.

Genetic testing

Cell-free DNA Testing (Liquid Biopsy) for the Management of Cancer: 

• Expanded criteria to include a wider scope of testing for metastatic disease: AKT1 and PTEN (related to capivasertib/fulvestrant therapy)

Prenatal Testing [changed to Screening] using cell-free DNA:

• Expanded criteria to include follow-up screening for abnormal maternal serum screen results in viable singleton/twin pregnancies when diagnostic testing is declined
• Expanded criteria to include screening for pregnancies with multiple anomalies when diagnostic testing is not possible

Somatic Testing of Solid Tumors:

• Tissue-agnostic testing for patients with advanced solid tumors:
  • Clarification about TMB testing by FDA-approved test with reporting threshold ≥ 10 mutations/megabase (mut/Mb)
• Bladder cancer:
  • Expansive changes for microsatellite instability/mismatch repair deficiency (MSI/dMMR)
• Brain cancer:
  • New clinical criteria considered clarifications for what may have otherwise been reviewed using general (umbrella) criteria
• Breast cancer, metastatic:
  • Expanded criteria to include a wider scope of testing for metastatic disease:  AKT1 and PTEN (related to capivasertib/fulvestrant therapy)
• Colorectal cancer, localized and metastatic:
  • Newly diagnosed localized or metastatic CRC — Expanded criteria for MSI/dMMR testing to allow in individuals with de novo metastatic disease
  • Metastatic CRC — Expanded POLE/POLD1 testing
• Endometrial carcinoma:
  • Expanded routine testing for MSI/dMMR; also expanded POLE and p53 testing
  • Panel size limited to ≤ 50 genes
• Non-small cell lung cancer, metastatic:
  • New criteria for metastatic squamous cell carcinoma
  • Allowance for repeat NGS testing in the setting of progressive disease, if a progressing lesion is being used for the repeat testing
• Ovarian (epithelial):
  • Added statement that HRD testing must include evaluation of genomic instability through an FDA approved test
• Pancreatic adenocarcinoma:
  • Added criteria for targeted (50 or fewer genes) somatic testing beyond MSI/dMMR in locally advanced, metastatic, or recurrent pancreatic adenocarcinoma
• Prostate cancer, metastatic:
  • Specified appropriateness of MSI/dMMR testing is in metastatic prostate cancer
  • Moved ATM from required to "may be included" genes in approvable NGS panels
• Thyroid cancer:
  • Testing of indeterminate thyroid nodules (ITN) — Afirma GSC added as a gene expression classifier that may be used
  • Somatic testing of thyroid malignancy — Modified language so that BRAF V600E, ALK, NTRK, and RET testing can be done in anaplastic thyroid cancer at any stage, or in unresectable, locally advanced, recurrent, or metastatic thyroid cancer

Somatic Testing of Hematologic Malignancies:

• Acute Lymphocytic Leukemia:
  • Added statement about NGS testing on bone marrow specimen which specifies time points where testing is appropriate (such as, end of initial induction, end of initial consolidation)
• Acute Myelogenous Leukemia:
  • Added an indication for focused testing using RT-qPCR to measure minimal residual disease (MRD)
• Chronic Myeloid Leukemia:
  • Modified the timing for BCR-ABL1 quantification for monitoring in the first year after completion of tyrosine kinase inhibitor (TKI) therapy
  • Added allowance for BCR-ABL1 quantification for monitoring patients at three-month intervals beyond one year after completion of TKI therapy
• Myeloproliferative Neoplasms:
  • Added allowance for additional focused testing for initial risk stratification if a specific myeloproliferative neoplasm is diagnosed on initial diagnostic workup
• Myelodysplastic Syndrome:
  • Clarified that testing can be pursued for diagnosis or risk stratification and clarified the list of genes that may be associated with MDS

Musculoskeletal

Joint Surgery:

• Reverse Shoulder Arthroplasty:
  • Added a requirement for impaired function for six months for consistency with total shoulder arthroplasty
  • Removed requirement for conservative management when there is severe osteoarthritis for consistency with other joint replacements
• Shoulder Arthroscopy and Open Procedures:
  • Removal of loose body — Removed requirement for specific findings on exam
  • Rotator cuff repair and revision — Added an exclusion for subacromial balloon spacer due to lack of supporting evidence
  • Labrum Repair — Removed Bankart lesion broadening MRI findings to allow for any labral tear
  • Chronic shoulder instability or laxity — Broadened exam findings to include any evidence of instability rather than just the apprehension/relocation test
  • Tendinopathy of the long head of the biceps — Removed specific exam findings related to long head of biceps pathology
• Primary Total Hip Arthroplasty:
  • Removed the requirements for conservative management and three-month duration of symptoms when radiographs show severe osteoarthritis
• Primary Partial Hip Arthroplasty:
  • Combined criteria for partial hip arthroplasty and partial hip resurfacing
• Hip Arthroscopy:
  • Removal of loose body — Removed requirement for specific findings on exam
• Knee Arthroplasty:
  • Added exclusion for the use of an implantable shock absorber due to lack of supporting evidence
• Knee Arthroscopy:
  • ACL reconstruction — Removed standalone scenario of physically demanding occupation/pattern of activities
  • Excision of popliteal cyst — Added imaging requirement
  • Repair of subchondral bone defects (subchondroplasty) — Added exclusion for use of engineered calcium phosphate mineral or similar compounds due to lack of supporting evidence
• Osteochondral Grafts:
  • Juvenile Osteochondritis Dissecans — Expanded allowances to include either failed conservative management or unstable lesion
  • Added exclusion for use of particulated juvenile articular cartilage due to lack of evidence supporting its use

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management using the following:

• Access Carelon Medical Benefits Management’s provider portal directly at providerportal.com:
  • Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.

The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third-Party Criteria below were developed and/or revised during Quarter 1, 2024. Note, several policies and guidelines were revised to provide clarification only and are not included. Some may have expanded rationales, medical necessity indications or criteria and some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary.

Please share this notice with other providers in your practice and office staff.

To view a guideline, visit anthem.com/medicareprovider and select Change State and pick appropriate state. Then Providers > Policies, Guidelines & Manuals.

Notes/Updates:

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

• LAB.00039 - Combined Pathogen Identification and Drug Resistance Testing; Previously Titled: Pooled Antibiotic Sensitivity Testing

• Revised title
• Revised Position Statement to address “combined pathogen identification and drug resistance” testing

• OR-PR.00008 - Osseointegrated Limb Prostheses
  • Outlines the Medically Necessary and Not Medically Necessary criteria for the use of osseointegrated (bone-anchored) prosthetic devices for improving the mobility and function of people who have had limb loss
• SURG.00052 - Percutaneous Vertebral Disc and Vertebral Endplate Procedures
  • Revised Medically Necessary criteria for basivertebral nerve ablation (BVNA)
• SURG.00162 - Implantable Shock Absorber for Treatment of Knee Osteoarthritis
  • Use of an implantable shock absorber device for treatment of osteoarthritis of the knee is considered Investigational & Not Medically Necessary
• CG-DME-53 - Biomechanical Footwear Therapy
  • Biomechanical footwear therapy is considered Not Medically Necessary for all indications
• CG-LAB-32 - Cancer Antigen 125 Testing
  • Outlines the Medically Necessary and Not Medically Necessary criteria for the tumor marker cancer antigen 125 (CA-125) testing
• CG-MED-94 - Vestibular Function Testing
  • Revised Medically Necessary and Not Medically Necessary statements to include vestibular-evoked myogenic potential tests
• CG-MED-96 - Prefabricated External Infant Ear Molding Systems
  • Outlines the Medically Necessary, Reconstructive and Cosmetic & Not Medically Necessary criteria for the use of prefabricated external infant ear molding systems to treat external ear malformations and deformations

Medical Policies

On February 15, 2024, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect August 8, 2024.

Clinical UM Guidelines

On February 15, 2024, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicare members on March 28, 2024. These guidelines take effect August 8, 2024.

The Medical Policy and Technology Assessment Committee (MPTAC) adopted the following new and/or revised Medical Policies and Clinical Guidelines. Some may have expanded rationales, medical necessity indications, or criteria, and some may involve changes to policy position statements that might result in services that previously were covered being found to be either not medically necessary or investigational/not medically necessary. Clinical Guidelines adopted by Anthem and all the Medical Policies are available here. Please note our Medical Policies now include not otherwise classified (NOC) codes to expedite the process of determining services that may require medical review.

If you do not have access to the Internet, you may request a hard copy of a specific Medical or Behavioral Health Policy or Clinical UM Guideline by calling Provider Services at 800-241-7475, Monday through Friday, from 8 a.m. to 7 p.m. You may also send written requests (specifying the policy or guideline of interest, your name, and address to where information should be sent) to:

Anthem                      
Attention: Prior Approval
Mail code GAG009-0002                              
3350 Peachtree Road NE                              
Atlanta, GA 30326                   

Note: Any Clinical Guideline included in this standard MPTAC notification is only effective for Georgia if included on the Georgia Standard Adopted Clinical Guideline list unless there is a group-specific review requirement. In this case, it will be considered adopted for that group only and for the specific type of review required. Additionally, as part of the Pre-Payment Review Program for Commercial or Federal Employee Health Benefits Program (FEHBP) plans, Clinical Guidelines approved by MPTAC but not included on the Georgia Standard Adopted Clinical Guideline list may be used to review a provider’s claims when a provider’s billing practices are not consistent with other providers in terms of frequency or in some other manner or for provider education. They are considered adopted for those purposes.

Anthem is in the process of shutting down specific authorization fax channels. This is to notify you the below fax numbers will be decommissioned as of August 30, 2024.

Look for additional notifications as other authorization fax lines are retired.

Availity Authorizations is the preferred method for authorization intakes. If you cannot use Availity Authorizations, call our contact center at 833-545-9102, and we will work with you to determine the best submission method.

Available resources

Registering and accessing Availity is easy. If your organization is not registered for Availity, start here.

If you are not already familiar with Availity Authorization, training is available. Register for training today and learn about the simple workflow for submitting digital authorizations.

These fax numbers will be turned off as of August 30, 2024.

Beginning with dates of service on or after November 1, 2024, Anthem will implement a new reimbursement policy titled Intraoperative Neuromonitoring — Professional based on guidelines from the American Academy of Neurology. This reimbursement policy will allow reimbursement for intraoperative neuromonitoring (IONM) when billed by a professional provider with a place of service 19, 21, 22, or 24.

When reporting IONM, providers are required to bill on a CMS-1500 form and use the appropriate place of service. Services must be performed in a hospital setting using the place of service where the member is located even if the monitoring physician is in an office. The following place of service codes are appropriate for use by the monitoring physician:

• Off campus-outpatient hospital (19)
• Inpatient hospital (21)
• On campus-outpatient hospital (22)
• Ambulatory surgical center (24)

For specific policy details, visit reimbursement policy page at anthem.com.

Anthem updated the Modifiers 26 and TC — Professional reimbursement policy in October 2023. The statement below was inadvertently removed from the Nonreimbursable section of the policy, but remained in the policy Definition section:

• There is a separate standalone code that describes the professional component only, technical component only, or global test only of a selected diagnostic test.

 No claims were impacted by the omission of this statement. The Nonreimbursable section of the policy has been updated to include this statement. 

For specific policy details, visit the reimbursement policy page at anthem.com.

Beginning with dates of service on or after November 1, 2024, Anthem will update the Bundled Services and Supplies — Facility reimbursement policy as follows:

• Addition of categories of services considered integral to the primary service, or included in the facility fee that are not allowed for separate reimbursement when billed by a facility provider
• Addition of the following code to the Related Coding section:

• G2211 — visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed healthcare services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition

For specific policy details, visit the reimbursement policy page and select the appropriate state.

Past system limitations prevented us from reimbursing Modifier 78 in complete alignment with Centers for Medicare & Medicaid Services (CMS). New system updates will now allow Anthem to closer align with the CMS Medicare Physician Fee Schedule Data Base (MPFSDB).

For claims processed on and after 07/01/2024, you may see a slight adjustment in reimbursement which will reflect this configuration update.

For specific policy details visit the reimbursement policy page at anthem.com/medicareprovider.

Beginning with dates of service on or after November 1, 2024, Anthem will update the related coding section of the Outpatient Facility Revenue Code Billing Requirements — Facility reimbursement policy. The policy requires HCPCS or CPT^® codes to be submitted for reimbursement when submitted with certain revenue codes. The policy is updated to include the following revenue codes that require a corresponding HCPCS or CPT code:

• 0270 Medical/Surgical Supplies and Devices — General
• 0271 Medical/Surgical Supplies and Devices — Nonsterile
• 0272 Medical/Surgical Supplies and Devices — Sterile
• 0273 Medical/Surgical Supplies and Devices — Take-home supplies
• 0274 Medical/Surgical Supplies and Devices — Prosthetic/orthotic devices
• 0275 Medical/Surgical Supplies and Devices — Pacemaker
• 0276 Medical/Surgical Supplies and Devices — Intraocular lens
• 0277 Medical/Surgical Supplies and Devices — Take-home oxygen
• 0279 Medical/Surgical Supplies and Devices — Other supplies/devices
• 0280 Oncology — General
• 0920 Other diagnostic services — General
• 0940 Other therapeutic services — General

For specific policy details, visit the reimbursement policy page at anthem.com.

Beginning with dates of service on or after 11/01/2024, Anthem will update the Nurse Practitioner and Physician Assistant Services reimbursement policy as indicated below.

The following services will be removed as physicians’ services:

• Preventive Services
• Radiology Services

The following services will be included as physicians’ services:

• Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS)
• Laboratory Services and Screening Services

For specific policy details, visit the reimbursement policy page at Anthem.com/provider.

Specialty pharmacy updates for Anthem are listed below

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company.

Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications.

Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Prior authorization updates

Update: In the May 2023 edition of Provider News, we announced prior authorization for Adstiladrin would be effective August 2023. Review of Adstiladrin is managed by Carelon Medical Benefits Management.

Effective for dates of service on and after May 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process.

Access our Clinical Criteria to view the complete information for these prior authorization updates.

* Oncology use is managed by Carelon Medical Benefits Management.

Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.

Quantity limit updates

Effective for dates of service on and after May 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process.

Access our Clinical Criteria to view the complete information for these quantity limit updates.

Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners.

Specialty pharmacy updates for Anthem are listed below.

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company.

Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications.

Inclusion of a national drug code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

Prior authorization updates

Effective for dates of service on or after November 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process.

Access our Clinical Criteria at anthem.com/ms/pharmacyinformation/clinicalcriteria.html to view the complete information for these prior authorization updates.

* Oncology use is managed by Carelon Medical Benefits Management.

Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.

Quantity limit updates

Effective for dates of service on or after November 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process. 

Access our Clinical Criteria at anthem.com/ms/pharmacyinformation/clinicalcriteria.html to view the complete information for these quantity limit updates.

Effective for dates of service on and after November 1, 2024, the following Clinical Criteria were developed and might result in services that were previously covered but may now no longer be identified as medically necessary.

Access the Clinical Criteria information online.

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by Carelon Medical Benefits Management, Inc., a separate company.